NMTC earnings
NeuroOne Medical Technologies Corporation (NMTC) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company Highlights Product revenue increased 105% to $1.7 million in the third quarter of fiscal year 2025, compared to $0.8 million in the third quarter of fiscal year 2024.Product gross margin expanded significantly to 53.9% in the third
- NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - UpdateEDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, August 14, 2025, to discuss the Company's third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use
- NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern TimeEDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, May 14, 2025, to discuss the Company's third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the
- NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati
- NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern TimeEDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f
- NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate UpdateTotal revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal
- NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern TimeEDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025. Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wednesday, February 12, 2025, to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the
- NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter and Fiscal Year 2024 Financial Highlights Product revenue increased 77% to $3.5 million in fiscal year 2024, compared to $2.0 million in fiscal 2023. Revenue was l
- NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern TimeEDEN PRAIRIE, Minn., Dec. 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for the fiscal fourth quarter and year ended September 30, 2024, before market open on December 17, 2024. Management will host an investor conference call and webcast at 9:00 a.m. Eastern time on Tuesday, December 17, 2024 to discuss the Company's fourth quarter and fiscal year 2024 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To pa
- NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in Q3 2024Raised an additional $1.6 million using the ATM Program in Q3 2024Completed $2
- NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update. Conference Call and Webcast Information: Wednesday, August 14, 2024 – 4:30 PM Eastern Time Participants: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 579769 Phone Replay:
- NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo® sEEG: Zimmer Biomet continued to expand into new a
- NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update. Conference Call and Webcast Information: Tuesday, May 14, 2024 – 4:30 PM Eastern Time Participant Dial-In:Toll Free: 888-506-0062International: 973-528-0011Access Code: 489972 Live Webcast: Join here.
- NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the first quarter fiscal year 2024 ended December 31, 2023. First Quarter Fiscal Year 2024 and Recent Business UpdatesFinancial Highlights: Product revenue of $978,000 in Q1 2024, compared to $115,000 in Q1 2023 Raised an additional $2.8 million using the ATM Offering in December 2023 and January 2024 Evo® sEEG: Customer feedback remains positive as commercial la
- NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update. Conference Call and Webcast Information: Tuesday, February 13, 2024 – 4:30 PM Eastern Time Participant Dial-In:888-506-0062 / +1 973-528-0011 Access Code: 540724 Live Webcast: Join here.
- NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2023, and provide a corporate update, on December 14, 2023 at 5:00 PM Eastern Time. Conference Call and Webcast Information: Thursday, December 14, 2023 – 5:00 PM Eastern Time Participant Dial-In:877-405-1216 / +1 201-689-8336 Live Webcast: Join here. Phone Replay: 877-660-6853 / 201-612-7
- NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Monday, August 14, 2023 – 4:30 PM Eastern Time Participant Dial-In:800-267-6316 / +1 203-518-9783Conference ID (required for entry): NEURO Live Webcast: Join here. Phone Replay: 877-660-
- NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal second quarter 2023 ended March 31, 2023. Fiscal Second Quarter 2023 and Recent Business Updates Evo® sEEG: Announced the commercial launch of the Evo sEEG electrode product line in the United States with exclusive distribution partner Zimmer Biomet. The new technology potentially provides NeuroOne with a new revenue stream.The first clinical case us
- NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Thursday, May 11, 2023 – 4:30 PM Eastern Time Participant Dial-In:888-645-4404 / 862-298-0702 Live Webcast: Join here. Phone Replay: 877-660-6853 / 201-612-7415, Access ID: 13738525
- NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., Feb. 14, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022. Fiscal First Quarter 2023 and Recent Business Updates Received FDA 510(k) clearance to market the Evo® sEEG Electrode technology for temporary (less than 30 day) use with recording, monitoring, and stimulation e
- NeuroOne® to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14EDEN PRAIRIE, Minn., Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Tuesday, February 14, 2023 – 4:30 PM Eastern Time Participant Dial-In:877-40
- NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial ResultsEDEN PRAIRIE, Minn., Dec. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC, ", NeuroOne", or the ", Company", ))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces financial results for the fiscal fourth quarter and full fiscal year ended September 30, 2022. Dave Rosa, CEO of NeuroOne, commented, "The Company made great progress in fiscal 2022 in a wide variety of areas including commercialization, development and capital raises, which will allow us
- NeuroOne® to Host Fiscal Fourth Quarter Corporate UpdateEDEN PRAIRIE, Minn., Dec. 13, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC, ", NeuroOne", or the ", Company", ))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, to host fiscal Fourth Quarter Corporate Update for the period ended September 30, 2022. Fourth Quarter and Recent Business Highlights Received a $3.5 million accelerated payment from distribution partner Zimmer Biomet related to certain milestone events; Zimmer Biomet received a Warrant to purchase
- NeuroOne® to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide Corporate Update on December 13EDEN PRAIRIE, Minn., Dec. 8, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2022, and provide a corporate update, on December 13, 2022 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Tuesday, December 13, 2022 – 4:30 PM Eastern Time Partic
- NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., Aug. 11, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022. Third Quarter and Recent Business Updates Zimmer Biomet agreed to an accelerated $3.5M milestone payment for Evo® sEEG electrode; Zimmer received a warrant to purchase 350,000 shares of NeuroOne's common sto
- NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11EDEN PRAIRIE, Minn., Aug. 4, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter of fiscal 2022 ended June 30, 2022, on August 11, 2022 at 5:30 PM Eastern Time. Conference Call and Webcast Information: Thursday, August 11, 2022 – 5:30 PM Eastern Time Participant Dial-In:877-407-8293 / +1 201-689-8349 Live Web
- NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate UpdateEDEN PRAIRIE, Minn., May 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022. Second Quarter and Recent Business UpdatesEvo® sEEG electrode first commercial order is in inventory and ready to ship pending FDA clearance for less than 30 day duration of use. The Evo sEEG electrode was
- NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12EDEN PRAIRIE, Minn., May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time. Conference Call and Webcast Information: May 12, 2022 – 4:30 PM Eastern Time Participant Dial-In:877-407-8293 / +1 201-689-8349 Live Webcast: https://e
- NeuroOne® Investor Call Replay Available Through April 11thEDEN PRAIRIE, Minn., March 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that a telephone replay of its investor conference call discussing recent disclosures, held yesterday, will be available through April 11, 2022. The webcast replay will be available for one year. During the investor call, NeuroOne CEO Dave Rosa was joined by Dr. William Wustenberg, a biocom
- NeuroOne® to Host Investor Call About Recent Disclosures Tomorrow March 29th at 10:00 am ETEDEN PRAIRIE, Minn., March 28, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will host a conference call to discuss recent disclosures tomorrow, March 29, 2022, at 10:00 am Eastern Time. The purpose of the call is to provide clarification and answer questions regarding disclosure included in the Company's recent Current Report on Form 8-K filed on Friday, March 25, 2022 about its 510(k) clearance request to the FDA for its Evo® sEEG Electrode for less than 30-day use. The
- NeuroOne to Host First Quarter Fiscal Year 2022 Earnings CallEDEN PRAIRIE, Minn., Feb. 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its first quarter of fiscal 2022, ended December 31, 2021, on February 14, 2022 at 4:30 PM Eastern Time. Conference Call Information Event Date: February 14, 2022 - 4:30 PM Eastern Time Participant Numbers: Toll Free: 888-506-006
- NeuroOne to Host Fourth Quarter 2021 Earnings CallEDEN PRAIRIE, Minn., Dec. 6, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2021, on December 15, 2021, at 9:00 AM Eastern Time. Conference Call Information Event Date: December 15, 2021 - 9:00 AM Eastern Time Participant Dial-in Numbers:Toll Free: 8
- NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate UpdateEDEN PRAIRIE, Minn., Aug. 13, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC, ", NeuroOne", or the ", Company", ))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter ended June 30, 2021. Third Quarter and Fiscal 2021 Recent Business Updates Uplisted to the Nasdaq Capital Market under existing ticker symbol "NMTC" Launched the first product, the Evo Cortical Electrode, with Zimmer Biomet Submitted a 510(k) to FDA for Company's Evo sEEG Electrode Initiated testing for electrodes intended to provide therapeutic stimulation for bac
- NeuroOne to Host Third Quarter 2021 Earnings CallEDEN PRAIRIE, Minn., Aug. 11, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its third quarter ended June 30, 2021, on August 13, 2021, at 9:00 AM ET. Conference Call Information Dial-in: (346) 248-7799Meeting ID: 95665935395Passcode: 902419Webcast: https://audience.mysequire.com/webinar-view